KR100691654B1 - 테트라시클린 화합물을 이용한 인터루킨-10 생성을촉진하는 방법 - Google Patents

테트라시클린 화합물을 이용한 인터루킨-10 생성을촉진하는 방법 Download PDF

Info

Publication number
KR100691654B1
KR100691654B1 KR1020017002727A KR20017002727A KR100691654B1 KR 100691654 B1 KR100691654 B1 KR 100691654B1 KR 1020017002727 A KR1020017002727 A KR 1020017002727A KR 20017002727 A KR20017002727 A KR 20017002727A KR 100691654 B1 KR100691654 B1 KR 100691654B1
Authority
KR
South Korea
Prior art keywords
cmt
tetracycline
production
delete delete
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017002727A
Other languages
English (en)
Korean (ko)
Other versions
KR20010074919A (ko
Inventor
고룹로르네엠.
리츠린크리스토퍼티.
그린왈드로버트에이.
하스-스미스샐리
모크수잔에이.
리시-밍
Original Assignee
더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕
유니버시티 오브 로체스터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕, 유니버시티 오브 로체스터 filed Critical 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕
Publication of KR20010074919A publication Critical patent/KR20010074919A/ko
Application granted granted Critical
Publication of KR100691654B1 publication Critical patent/KR100691654B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020017002727A 1998-09-11 1999-09-10 테트라시클린 화합물을 이용한 인터루킨-10 생성을촉진하는 방법 Expired - Fee Related KR100691654B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/151,534 US6015804A (en) 1998-09-11 1998-09-11 Method of using tetracycline compounds to enhance interleukin-10 production
US09/151,534 1998-09-11

Publications (2)

Publication Number Publication Date
KR20010074919A KR20010074919A (ko) 2001-08-09
KR100691654B1 true KR100691654B1 (ko) 2007-03-09

Family

ID=22539191

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017002727A Expired - Fee Related KR100691654B1 (ko) 1998-09-11 1999-09-10 테트라시클린 화합물을 이용한 인터루킨-10 생성을촉진하는 방법

Country Status (14)

Country Link
US (1) US6015804A (https=)
EP (1) EP1119362B1 (https=)
JP (3) JP2002524521A (https=)
KR (1) KR100691654B1 (https=)
AT (1) ATE317262T1 (https=)
AU (1) AU754515B2 (https=)
CA (1) CA2339667C (https=)
CY (1) CY1107495T1 (https=)
DE (1) DE69929810T2 (https=)
DK (1) DK1119362T3 (https=)
ES (1) ES2258854T3 (https=)
NZ (1) NZ509799A (https=)
PT (1) PT1119362E (https=)
WO (1) WO2000015235A1 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429204B1 (en) * 1997-01-15 2002-08-06 University Of Miami Method of inhibiting cancer growth
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
US20020132798A1 (en) * 2000-06-16 2002-09-19 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
AU2002303250B2 (en) * 2001-04-05 2006-05-25 Collagenex Pharmaceuticals, Inc. Methods of treating acne
AU2002256092C1 (en) * 2001-04-05 2009-10-15 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
EP2329826A1 (en) 2001-07-13 2011-06-08 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of multiple sclerosis
US20110092677A1 (en) * 2001-08-30 2011-04-21 Biorexis Technology, Inc. Modified transferin-antibody fusion proteins
EP2311799A1 (en) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
EP1572078A4 (en) * 2002-03-08 2006-08-09 Univ Emory NEW CURCUMINOID FACTOR VIIa CONSTRUCTS AS MEANS OF SUPPRESSING TUMOR GROWTH AND ANGIOGENESIS
JP2005526754A (ja) 2002-03-08 2005-09-08 パラテック ファーマシューティカルズ インコーポレイテッド アミノメチル置換されたテトラサイクリン化合物
KR101083498B1 (ko) 2002-03-21 2011-11-16 파라테크 파마슈티컬스, 인크. 치환된 테트라시클린 화합물
WO2003082011A1 (en) * 2002-03-29 2003-10-09 The Research Foundation Of State University Of New York Use of non-antibacterial tetracycline analogs and formulations thereof for the treatment of bacterial exotoxins
US6958161B2 (en) 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
US8192749B2 (en) 2003-04-16 2012-06-05 Galderma Laboratories Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
US20050153943A1 (en) * 2002-05-06 2005-07-14 Ashley Robert A. Methods of simultaneously treating mucositis and fungal infection
CA2492273C (en) 2002-07-12 2013-02-05 Paratek Pharmaceuticals, Inc. 3, 10, and 12a substituted tetracycline compounds
ES2534827T3 (es) 2003-04-07 2015-04-29 Supernus Pharmaceuticals, Inc. Formulaciones de tetraciclinas en dosis única diaria
JP4738333B2 (ja) 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド ９−アミノメチルテトラサイクリン化合物のプロドラッグ
CA2531728A1 (en) 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
NZ547628A (en) * 2003-11-06 2010-07-30 Univ New York State Res Found Methods of treating eczema
CA2553510C (en) * 2004-01-15 2012-09-25 Paratek Pharmaceuticals, Inc. Aromatic a-ring derivatives of tetracycline compounds
AU2005299294B2 (en) 2004-10-25 2012-06-07 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
EP2269985A3 (en) 2004-10-25 2011-09-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
AU2006247249A1 (en) * 2005-05-16 2006-11-23 Children's Medical Center Corporation Method of treating Lymphangioleiomyomatosis (LAM)
US8252776B2 (en) * 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US9192615B2 (en) 2008-08-06 2015-11-24 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
JP2009502809A (ja) * 2005-07-21 2009-01-29 パラテック ファーマシューティカルズ インコーポレイテッド １０−置換テトラサイクリンおよびその使用方法
WO2007075794A2 (en) * 2005-12-22 2007-07-05 Wyeth Oral formulations comprising tigecycline
BRPI0620430A2 (pt) * 2005-12-22 2011-11-08 Wyeth Corp métodos para tratar infecções do trato gastrointestinal com tigeciclina
PT2120963T (pt) 2006-12-21 2018-12-17 Paratek Pharm Innc Compostos tetraciclina substituídos para tratamento de distúrbios inflamatórios da pele
PL2109602T3 (pl) * 2006-12-21 2014-09-30 Paratek Pharm Innc Pochodne tetracyliny do leczenia zakażeń bakteryjnych, wirusowych i pasożytniczych
JP2010525069A (ja) * 2007-04-27 2010-07-22 パラテック ファーマシューティカルズ インコーポレイテッド アミノアルキルテトラサイクリン化合物の合成方法および精製方法
BRPI0823405A2 (pt) * 2007-07-06 2012-12-25 Paratek Pharmaceuticals, Inc. mÉtodos para sintetizar compostos de tetraciclina substituÍda
TW202216656A (zh) 2008-05-19 2022-05-01 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體
PT2323972E (pt) 2008-08-08 2013-10-09 Tetraphase Pharmaceuticals Inc Compostos de tetraciclina substituídos com c7-flúor
EP2427425B1 (en) 2009-05-08 2017-03-08 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
IN2012DN02502A (https=) 2009-08-28 2015-08-28 Tetraphase Pharmaceuticals Inc
TWI592390B (zh) 2010-03-31 2017-07-21 四相製藥公司 聚環狀四環素化合物
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
BR112015004523B1 (pt) 2012-08-31 2020-08-04 Tetraphase Pharmaceuticals, Inc Compostos de tetraciclina, composições farmacêuticas e seus usos
KR20180022664A (ko) * 2015-06-30 2018-03-06 필립모리스 프로덕츠 에스.에이. 개선된 개방을 갖는 용기
CN110582486B (zh) 2016-10-19 2024-01-12 四相制药公司 艾若威四环素的结晶形式
US12570604B2 (en) 2018-11-09 2026-03-10 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a tetracycline compound and uses thereof
CN118045037A (zh) * 2022-11-17 2024-05-17 中南大学湘雅二医院 一种地美环素盐滴眼液或注射液及其制备方法以及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4505896A (en) * 1979-04-19 1985-03-19 Elorac, Ltd. Method of treating acne vulgaris and composition
US5532227A (en) * 1992-11-17 1996-07-02 The Research Foundation Of State University Of New York Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive glycosylation of different types of collagen and other proteins during diabetes
EP0736302A2 (en) * 1995-03-23 1996-10-09 Stichting REGA V.Z.W. Protease inhibitors, a DNA construct for the expression of a protease and a process for measuring proteases and/or protease inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704383A (en) * 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
JP3016587B2 (ja) * 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5045538A (en) * 1990-06-28 1991-09-03 The Research Foundation Of State University Of New York Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines
US5258371A (en) * 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US5368854A (en) * 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
US5665345A (en) * 1993-05-24 1997-09-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting viral replication using IL-10
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5650396A (en) * 1994-03-15 1997-07-22 Celtrix Pharmaceuticals, Inc. Methods of modulating inflammatory cytokines in the CNS using TGF-β
US5827840A (en) * 1996-08-01 1998-10-27 The Research Foundation Of State University Of New York Promotion of wound healing by chemically-modified tetracyclines
US5789395A (en) * 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5837696A (en) * 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
JP2908375B2 (ja) * 1997-04-01 1999-06-21 ザ リサーチ ファンデーション オブ ステート ユニバーシティ オブ ニューヨーク 非抗バクテリア性テトラサイクリン組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4505896A (en) * 1979-04-19 1985-03-19 Elorac, Ltd. Method of treating acne vulgaris and composition
US5532227A (en) * 1992-11-17 1996-07-02 The Research Foundation Of State University Of New York Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive glycosylation of different types of collagen and other proteins during diabetes
EP0736302A2 (en) * 1995-03-23 1996-10-09 Stichting REGA V.Z.W. Protease inhibitors, a DNA construct for the expression of a protease and a process for measuring proteases and/or protease inhibitors

Also Published As

Publication number Publication date
CA2339667C (en) 2010-05-18
CY1107495T1 (el) 2013-03-13
KR20010074919A (ko) 2001-08-09
WO2000015235A1 (en) 2000-03-23
JP2010053146A (ja) 2010-03-11
NZ509799A (en) 2003-08-29
DE69929810T2 (de) 2006-11-02
ES2258854T3 (es) 2006-09-01
CA2339667A1 (en) 2000-03-23
JP4929341B2 (ja) 2012-05-09
AU754515B2 (en) 2002-11-21
EP1119362A1 (en) 2001-08-01
JP2011148838A (ja) 2011-08-04
EP1119362B1 (en) 2006-02-08
DK1119362T3 (da) 2006-06-12
ATE317262T1 (de) 2006-02-15
JP2002524521A (ja) 2002-08-06
DE69929810D1 (de) 2006-04-20
PT1119362E (pt) 2006-06-30
US6015804A (en) 2000-01-18
EP1119362A4 (en) 2003-03-12
AU6142699A (en) 2000-04-03

Similar Documents

Publication Publication Date Title
KR100691654B1 (ko) 테트라시클린 화합물을 이용한 인터루킨-10 생성을촉진하는 방법
KR100554859B1 (ko) 일산화질소 생산을 억제하기 위한 테트라사이클린 화합물을 포함하는 약제학적 조성물
KR100982753B1 (ko) 테트라사이클린 화합물 및 테트라사이클린 유도체의 전달조절
US5308839A (en) Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
AU2002256092A1 (en) Controlled delivery of tetracycline compounds and tetracycline derivatives
JPH0780774B2 (ja) 薬剤組成物
JPH04230323A (ja) テトラサイクリン含有医薬組成物
CA2300289C (en) A pharmaceutical composition active in reducing production of mcp-1 protein
CN1057937C (zh) 溶菌酵素二聚体的新用途及其含有溶菌酵素二聚体的制剂
CA2235902C (en) Method for treating protozoal infections
RU2088239C1 (ru) Состав, проникающий через кожу, для лечения остеоартроза
WO2006036655A2 (en) Use of low dose chemically modified tetracyclines to reduce inflammatory mediators

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20120207

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20130201

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20140301

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140301